Clinical Trials Logo

Hyperlipoproteinemia Type II clinical trials

View clinical trials related to Hyperlipoproteinemia Type II.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03756779 Withdrawn - Clinical trials for Familial Hypercholesterolemia

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

We are performing a pilot cross-over diet study involving 5 patients with heterozygous FH and 5 patients with unexplained ADH. The patients will be randomized to a low versus high saturated fat diet for 4 weeks each. We hypothesize that patients with unexplained ADH may have an exaggerated cholesterol response to saturated fat intake. The specific aim of this study is to quantify the increase in LDL-C in unexplained ADH patients compared to FH patients. The pilot study proposed here will develop preliminary data to be used for future funding proposals of larger, randomized studies.

NCT ID: NCT03455777 Withdrawn - Clinical trials for Homozygous Familial Hypercholesterolemia

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Start date: April 12, 2018
Phase: Phase 2
Study type: Interventional

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).

NCT ID: NCT03198897 Withdrawn - Clinical trials for Lipoprotein Lipase Deficiency

Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)

BioHoFH
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Homozygous familial Hypercholesterolemia from blood

NCT ID: NCT02765841 Withdrawn - Clinical trials for Homozygous Familial Hypercholesterolemia

Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy

Start date: May 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3 single-arm, open-label, international, multi-center clinical trial to evaluate the efficacy and safety of lomitapide in pediatric patients with HoFH who are receiving stable lipid-lowering therapy, including LDL apheresis. The study is comprised of a 12-week Run-in Period, a primary 24-week Efficacy Phase, followed by an 80-week Safety Phase.

NCT ID: NCT02399852 Withdrawn - Clinical trials for Homozygous Familial Hypercholesterolemia

Effects of Lomitapide on Carotid and Aortic Atherosclerosis

Start date: June 2015
Phase: N/A
Study type: Observational [Patient Registry]

Study to assess changes in carotid and aortic atherosclerosis in patients being treated with lomitapide.

NCT ID: NCT00751608 Withdrawn - Clinical trials for Familial Hypercholesterolemia

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

Start date: September 2006
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect of APL180 on endothelial function measured by forearm venous occlusion plethysmography in patients with familial hypercholesterolemia.